DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbookMLAMSRAFoundationMRCS

Neutrophilia, lymphocytosis and reactive leucocytosis

Interpret raised white-cell counts by lineage, time course and morphology, recognise reactive physiological and infective patterns, and escalate blasts, clonal lymphocytosis or unexplained persistence appropriately.

!
Time-critical presentation

A very high white count with dyspnoea, hypoxia, confusion, focal neurology, retinal change or priapism can indicate leukostasis in acute leukaemia and requires immediate haematology and critical-care involvement. Do not assume sepsis and give large fluid loads blindly. Blasts, promyelocytes with coagulopathy, tumour-lysis biochemistry or haemodynamic sepsis each activate their own urgent pathway.

Open the sections you need. The overview is shown first.
01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Circulating white cells reflect marrow production, release from storage, margination and tissue migration. Acute catecholamine stress moves cells from vessel walls into the measured pool within minutes. Corticosteroids reduce egress and increase demargination. Infection and inflammation increase cytokine-driven production and release, sometimes including bands and earlier myeloid forms. These mechanisms can overlap after surgery or trauma, so count direction, differential, film and physiology are more informative than one threshold.

Lymphocytosis requires age-aware interpretation and morphology. Activated pleomorphic lymphocytes support viral immune stimulation; a monotonous population suggests a clone but is not diagnostic visually. In adults, persistent unexplained lymphocytosis is assessed with flow cytometry to establish clonality and phenotype. A small clonal B-cell population without lymphadenopathy, organ enlargement or cytopenia may be monoclonal B-cell lymphocytosis rather than chronic lymphocytic leukaemia, and management is usually observation rather than automatic treatment.

High-risk patterns are separated first. Blasts, anaemia, thrombocytopenia, coagulopathy, tumour-lysis abnormalities or leukostasis symptoms demand urgent haematology. Basophilia and a broad myeloid spectrum suggest CML; dysplasia or monocytosis may point to another myeloid neoplasm. Otherwise, investigate infection, inflammation, medicines, smoking and physiological context, then repeat after the trigger resolves. Persistent unexplained elevation needs a structured referral even if the patient feels well.

Key points

  • Leucocytosis is a laboratory description; classify the absolute neutrophil, lymphocyte, monocyte, eosinophil and basophil counts rather than interpreting the total alone.
  • Neutrophilia commonly accompanies bacterial infection, inflammation, tissue necrosis, corticosteroids, smoking, pregnancy, G-CSF, stress and splenectomy.
  • Reactive lymphocytosis is common in viral infection and can show large activated lymphocytes; pertussis and some bacterial or parasitic infections also raise lymphocytes.
  • Corticosteroids cause neutrophil demargination with lymphopenia and eosinopenia, often without the left shift or toxic change expected in intense bacterial inflammation.
  • A blood film can identify toxic granulation, Döhle bodies, reactive lymphocytes, blasts, dysplasia, smudge artefact and immature myeloid cells and is central to triage.
  • Basophilia, persistent myeloid left shift and splenomegaly raise chronic myeloid leukaemia and warrant BCR::ABL1 testing through haematology.
  • Persistent clonal-appearing lymphocytosis, lymphadenopathy, splenomegaly, cytopenias or B symptoms prompts flow cytometry and a lymphoproliferative pathway.
  • Repeat a clinically plausible reactive count after recovery because trajectory often separates transient response from a persistent clonal process.
  • Leukaemoid reactions can reach striking counts in severe infection, inflammation or growth-factor exposure, but magnitude alone cannot reliably distinguish them from myeloid neoplasia.
  • Treat the underlying cause rather than the number in uncomplicated reactive leucocytosis; cytoreduction is reserved for specialist malignant or hyperviscosity indications.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
01

Inflammatory cytokine response

Infection, necrosis and autoimmune inflammation stimulate marrow production and release of neutrophils, sometimes with immature granulocytes and toxic morphological change.

02

Demargination and redistribution

Catecholamines, corticosteroids, exercise and acute stress move leucocytes between marginated, circulating and tissue pools without requiring new cell production.

03

Reactive lymphoid stimulation

Viral antigens, pertussis and other immune stimuli expand polyclonal lymphocytes, often generating morphologically varied activated cells and transient node enlargement.

04

Clonal haematopoiesis

Myeloid or lymphoid neoplasms produce persistent lineage expansion with characteristic morphology, immunophenotype and genetic abnormalities rather than a self-limited physiological response.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
  1. 1
    Marrow reserve release

    Cytokines liberate mature storage-pool neutrophils and later accelerate granulopoiesis, creating a left shift when demand exceeds mature-cell reserves.

  2. 2
    Steroid trafficking effect

    Glucocorticoids reduce endothelial adhesion and tissue egress, increasing measured neutrophils while often lowering lymphocytes and eosinophils.

  3. 3
    Clonal accumulation

    Oncogenic signalling or impaired apoptosis permits one white-cell population to expand, suppress normal marrow or infiltrate organs and sometimes create leukostasis.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Reactive neutrophil film

Toxic granulation, vacuolation, Döhle bodies and a proportionate left shift support intense inflammation alongside the clinical phenotype.

Steroid pattern

Neutrophilia beginning after glucocorticoids with lymphopenia and eosinopenia may reflect demargination, though infection still requires clinical assessment.

Reactive lymphocytes

Large pleomorphic lymphocytes with abundant basophilic cytoplasm during a compatible viral syndrome suggest polyclonal activation.

Myeloid clonal pattern

Basophilia, splenomegaly and a spectrum from mature neutrophils to myelocytes and metamyelocytes raises CML.

Leukostasis syndromeRed flag

New hypoxia, confusion, focal neurology or retinal disturbance with suspected acute leukaemia requires emergency cytoreduction planning.

05InvestigationsWhat to request, why it matters and how to interpret it.
Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

  1. 01
    Repeat full count with differentialFirst step
    Why
    Confirm lineage, persistence and associated cytopenias.
    Interpretation and limitations
    Absolute counts are more useful than percentages; falling haemoglobin or platelets strengthens concern for marrow replacement or consumption.
  2. 02
    Manual blood film
    Why
    Distinguish reactive morphology from blasts or clonal patterns.
    Interpretation and limitations
    Toxic change and pleomorphism support reactivity, while blasts, basophilia, dysplasia or monomorphic lymphocytes prompt haematology investigation.
  3. 03
    CRP, cultures and source-directed tests
    Why
    Investigate infection or inflammation from the presentation.
    Interpretation and limitations
    Markers are non-specific and can be blunted; culture and imaging follow symptoms rather than the white count alone.
  4. 04
    Peripheral blood flow cytometry
    Why
    Establish lymphocyte clonality and immunophenotype.
    Interpretation and limitations
    A clonal population is classified with absolute burden, nodes, spleen and cytopenias; clonality does not automatically require treatment.
  5. 05
    BCR::ABL1 testing
    Why
    Confirm suspected chronic myeloid leukaemia.
    Interpretation and limitations
    Request through haematology when persistent myeloid left shift, basophilia or splenomegaly supports the question; it is not a screening test for every neutrophilia.
  6. 06
    Bone-marrow and genetic studies
    Why
    Classify acute or chronic haematological neoplasia.
    Interpretation and limitations
    Morphology, flow, cytogenetics and molecular results are integrated urgently when blasts, unexplained persistence or multilineage abnormalities occur.
  7. 07
    Tumour-lysis profile
    Why
    Assess metabolic risk in suspected high-burden malignancy.
    Interpretation and limitations
    Potassium, phosphate, calcium, urate, LDH and creatinine guide immediate prophylaxis and treatment alongside haematology review.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
01

Acute leukaemia

Blasts, rapid cytopenias, bone pain, bruising, infection or tumour-lysis features indicate malignant precursor expansion requiring urgent marrow and genetic classification.

02

Chronic myeloid leukaemia

Persistent neutrophilia with myelocytes, metamyelocytes, basophilia and splenomegaly suggests BCR::ABL1-positive disease rather than a simple neutrophil stress response.

03

Chronic lymphocytic leukaemia

Persistent clonal B lymphocytes with a characteristic phenotype may represent CLL or monoclonal B-cell lymphocytosis depending on burden and clinical findings.

04

Severe bacterial infection

Neutrophilia with toxic granulation, left shift, fever and organ dysfunction supports infection, but overwhelming sepsis can instead produce a normal or low count.

07ManagementImmediate care, first-line treatment, alternatives and escalation.
01TriageFind malignant danger before explaining the countFirst stepA raised white-cell count is accompanied by systemic or haematological symptoms.
  1. 1Assess breathing, neurology, retina, bleeding, infection and spleen and review haemoglobin, platelets, film flags, coagulation and tumour-lysis markers.
  2. 2DefinitiveCall haematology immediately for blasts, promyelocyte concern, leukostasis physiology, major cytopenias or tumour lysis and avoid delaying definitive sampling.
  3. 3Treat sepsis and other physiological emergencies in parallel, recognising that infection and leukaemia can coexist.
02Reactive assessmentMatch lineage to trigger and timeNo immediate malignant feature is present and a reactive cause is plausible.
  1. 1Review infection, inflammation, tissue injury, pregnancy, smoking, exercise, surgery, splenectomy and exact timing of steroids, adrenaline or G-CSF.
  2. 2Use differential and film morphology to support the mechanism, ordering cultures, imaging or inflammatory tests only from clinical findings.
  3. 3Repeat the count after the expected recovery interval and refer unexplained persistence, progression or new lineage abnormalities.
03LymphocytosisDistinguish polyclonal activation from cloneThe absolute lymphocyte count remains raised or morphology appears monomorphic.
  1. 1Assess recent viral symptoms, lymph nodes, spleen, B symptoms, infections, haemoglobin and platelets and retrieve previous lymphocyte counts.
  2. 2Request flow cytometry through the local pathway for persistent unexplained adult lymphocytosis or suspicious morphology.
  3. 3Classify a clonal result by phenotype, burden and clinical findings, using observation for suitable monoclonal B-cell lymphocytosis and specialist staging for CLL.
Key medicines and prescribing safety2 treatments · regimens, roles and cautions
Prevents harm from treating a physiological laboratory response rather than the underlying condition.

No medicine for an uncomplicated reactive count

Do not prescribe cytoreduction or antimicrobial treatment solely for the white-cell number; treat a clinically defined infection, inflammation or exposure using its own regimen.

A reactive hypothesis requires follow-up to resolution; persistent, basophilic, blast-containing or symptomatic leucocytosis still needs haematology assessment.

Reduces malignant cell burden when leukostasis or another urgent leukaemia indication threatens organs.

Emergency cytoreduction

A haematologist selects hydroxycarbamide, leukapheresis or disease-specific induction according to leukaemia subtype, symptoms, count kinetics and tumour-lysis risk.

Do not begin empirically without preserving diagnostic samples and specialist direction; anticipate tumour lysis, cytopenias, infection and reproductive implications.

08ComplicationsImportant consequences, why they occur and why they matter clinically.
01

Leukostasis

Large poorly deformable malignant blasts obstruct microcirculation, causing respiratory or neurological dysfunction that may occur at different counts across leukaemia subtypes.

02

Tumour lysis

Rapid malignant-cell turnover releases potassium, phosphate and nucleic acids, producing acute kidney injury, hypocalcaemia and arrhythmia before or after treatment.

03

Diagnostic delay

Repeatedly attributing persistent elevation to smoking, steroids or infection can postpone diagnosis of a treatable myeloid or lymphoid neoplasm.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.
  • Repeat counts at an interval based on suspected trigger and severity, documenting whether each lineage is returning toward baseline.
  • Re-examine for nodes, spleen, fever, weight loss, bruising and infection when leucocytosis persists or increases.
  • During steroid or G-CSF exposure correlate count changes with dose timing and clinical infection rather than labelling all elevation drug related.
  • For a clonal lymphocyte population follow absolute count, haemoglobin, platelets, nodes, spleen, symptoms and infection burden under haematology.
  • In suspected leukaemia monitor potassium, phosphate, calcium, urate, LDH, creatinine, coagulation and organ symptoms during urgent treatment.
  • Close a reactive episode only after the driver and count have resolved or a documented alternative follow-up plan exists.
10Special situationsVariants, exceptions and circumstances that change the usual approach.

Absolute beats percentage

A high lymphocyte percentage during neutropenia may hide a normal absolute lymphocyte count, while the total can obscure lineage-specific expansion.

Steroids move cells

Demargination can increase measured neutrophils quickly without new marrow production, explaining tempo but never excluding simultaneous infection.

Magnitude is not mechanism

Severe infection can create a leukaemoid count and leukaemia can present modestly, so morphology and context outweigh a single number.

Clone does not equal treatment

Small clonal B-cell populations may require observation; symptoms, cytopenias and disease burden determine management rather than clonality alone.

11Common pitfallsFrequent interpretation and management errors.
  1. 01

    Interpreting total white count without the differential.

  2. 02

    Calling every steroid-associated rise infection free.

  3. 03

    Using count magnitude alone to diagnose leukaemia.

  4. 04

    Ignoring basophilia and splenomegaly in persistent neutrophilia.

  5. 05

    Treating monoclonal B-cell lymphocytosis automatically.

  6. 06

    Failing to repeat a presumed reactive abnormality.

Practice

Two practice questions

Question 1 of 20 correct
Haematology and transfusionOriginal SBA

Pattern suggesting CML

An adult has persistent neutrophilia, splenomegaly, basophilia and a film showing myelocytes and metamyelocytes across the granulocytic series. Which investigation is most appropriate?

Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom